We conducted a prospective, multicenter observational study of adults ( ) and children ( ) n p 1447 n p 144 with candidemia at tertiary care centers in the United States in parallel with a candidemia treatment trial that included nonneutropenic adults. Candida albicans was the most common bloodstream isolate recovered from adults and children (45% vs. 49%) and was associated with high mortality (47% among adults vs. 29% among children). Three-month survival was better among children than among adults (76% vs. 54%; P ! ). Most children received amphotericin B as initial therapy, whereas most adults received fluconazole. In .001 adults, Candida parapsilosis fungemia was associated with lower mortality than was non-parapsilosis candidemia (24% vs. 46%; ). Mortality was similar among subjects with Candida glabrata or non-glabrata P ! .001 candidemia; mortality was also similar among subjects with C. glabrata candidemia who received fluconazole rather than other antifungal therapy. Subjects in the observational cohort had higher Acute Physiology and Chronic Health Evaluation II scores than did participants in the clinical trial (18.6 vs. 16.1), which suggests that the former subjects are more often excluded from therapeutic trials.
fection, following infection due to coagulase-negative staphylococci, Staphylococcus aureus, and Enterococcus species [2, 7] . Candidemia has a significant impact on overall and cause-specific mortality rates and is associated with excessive morbidity and prolongation of hospital stay [15] [16] [17] [18] [19] . Furthermore, there has been a recent shift from Candida albicans to non-albicans species of Candida as dominant causative agents [4, 7, 10, 14, [20] [21] [22] [23] [24] . The clinical management of candidemia has also evolved during the past decade, and a number of clinical treatment trials have been performed [25] [26] [27] [28] [29] [30] . Therapeutic guidelines for the management of candidemia have been recently formulated on the basis of results of these trials [31] .
Despite significant advances in the understanding of candidemia, many important questions remain. How often do non-albicans species of Candida cause candidemia in patients at tertiary care medical centers in the United States? What impact on mortality, if any, is associated with this shift toward non-albicans species of Candida as causal agents of candidemia? How does candidemia differ between adults and children, and is there a difference between these groups with regard to therapeutic approach? Finally, are subjects who are enrolled in clinical trials for the treatment of candidemia representative of most patients with this disorder?
We conducted a prospective, multicenter, observational study among candidemic hospitalized adult and pediatric patients in parallel with a randomized therapeutic trial of nonneutropenic adult patients with candidemia from 1995 through 1997. The combined results of the epidemiological features of both cohorts, as well as the clinical and therapeutic aspects of the observational cohort, are presented herein.
PATIENTS AND METHODS

Observational cohort.
The NIH/NIAID Mycoses Study Group (MSG) Study 34, which was a prospective observational study, was conducted from February 1995 through November 1997 among hospitalized patients in parallel with a randomized trial comparing the effectiveness of high-dose fluconazole plus amphotericin B with that of high-dose fluconazole alone for the treatment of candidemia (MSG Study 33). Thirty-four tertiary care medical centers in the United States participated in the observational study, of which 27 also participated in the clinical trial. A large array of geographic and demographic diversity among patients in the United States was represented at the study sites (see below). Hospitalized patients who had у1 blood culture positive for Candida species and who were not participating in the treatment trial were eligible for enrollment.
Data on the observational study were recorded on a standardized case report form during review of medical charts and included demographic characteristics; risk factors associated with candidiasis; other comorbidities; duration of hospital stay, including the number of days in the intensive care unit (ICU); APACHE II scores (adults only); dates on which results of blood cultures were positive; antifungal therapy received; survival 3 months after the initial positive blood culture result; and time and cause(s) of death. Patients were considered adults if their age was у13 years. Follow-up 3 months after the initial positive blood culture result was performed via telephone contact with the primary care physician or, among patients hospitalized for a prolonged duration, via chart review. For patients who died during the 3-month follow-up period, cause-specific mortality (i.e., death attributed to candidemia) was defined as follows: (1) death р48 h after a blood culture positive for Candida species, (2) other clinical evidence of persistent candidiasis (e.g., persistent fever, hypotension, or cultures positive for Candida species at clinically involved sites, such as peritoneal fluid or renal abscess), (3) autopsy evidence of disseminated candidiasis, or (4) indication by the investigator that candidiasis significantly contributed to death.
Clinical trial cohort. Similar data from patients accrued into the concurrent randomized treatment trial (MSG Study 33) during the same period (February 1995 through November 1997) were included in this analysis. Therapeutic data from the clinical trial were not included in this analysis and are presented elsewhere [30] . In addition to patients with у1 blood culture positive for Candida species, the randomized clinical trial was limited to nonneutropenic adults who had clinical evidence of infection, had no significant preexisting renal or hepatic dysfunction, and had received a minimal amount of prior antifungal therapy.
Statistical analysis. Mycological and epidemiological data from both cohorts were merged. Descriptive statistics were used to summarize the data. The significance level for analysis was 0.05. Fisher's exact test and x 2 analyses were used to evaluate the association between individual risk factors and mortality in the observational cohort. Factors significantly associated with mortality in the univariate analysis that occurred in 110% of patients were evaluated in a stepwise logistic regression model.
RESULTS
Enrollment.
A total of 1471 patients were enrolled into the observational study. Twenty-four were ineligible because there was either no documentation of candidemia or inadequate baseline data. During this same period, 146 patients with candidemia were enrolled into the randomized clinical trial. Thus, we analyzed mycological and epidemiological data for 1593 patients, of whom 1447 were in the observational cohort and 146 were in the clinical trial. Three-month follow-up data were available for 1387 patients (96%) in the observational cohort and for 133 patients (92%) in the clinical trial.
Demographic characteristics and risk factors. Of a total of 1593 patients enrolled in the studies, 1449 (91%) were adults and 144 (9%) were children (table 1). Median age was 55 years among adults and 8 months among children; 91 children were !1 year old. Fifty-five percent and 51% of adults and children, respectively, were male. Overall, 56% of the patients were white, 28% were black, and 11% were Hispanic. Ninety-six percent of the patients had у1 significant underlying illness, 85% had у2, and 66% had у3. There were no significant differences between adults and children with respect to intravascular catheters in place, previous receipt of antibacterial or antifungal therapy, and previous receipt of systemic glucocorticosteroids. However, more adults than children were diabetic (29% vs. 3%), were undergoing hemodialysis (14% vs. 7%), and had received ablative chemotherapy (12% vs. 6%), radiation therapy (2) 371 (29) 44 (30) 418 (26) Trauma 2 (1) 108 (8) 12 (8) 122 (8) Neutropenia a 11 (8) 148 (11) 0 (0) 160 (10) Endotracheal intubation 100 (69) 622 (48) 45 (31) 791 (50) Neoplasia 11 (8) 374 (29) 31 (21) 416 (26) HIV infection with CD4 lymphocyte count of !200 cells/mm 3 5 (4) 63 (5) 3 (2) 71 (4) Urinary catheter 48 (33) 853 (66) 59 (40) 960 (60) Surgery 42 (29) 469 (36) 70 (48) 581 (36) Hemodialysis 3 (2) 183 (14) 9 (6) 195 (12) Peritoneal dialysis 1 (!1) 19 (2) 3 (2) 23 (1 (3% vs. 1%), cyclosporine (5% vs. 1%), or other immunosuppressive agents (6% vs. 2%). Conversely, more children than adults were endotracheally intubated (69% vs. 48%) and had received total parenteral nutrition (79% vs. 50%). Only 10% of the total number of patients (11% and 8% of adults and children, respectively) were neutropenic when candidemia was documented.
Mycological data. C. albicans was the most common bloodstream isolate recovered and was found in 45% and 49% of adults and children, respectively (table 2) . Candida glabrata and Candida parapsilosis were the second most common isolates recovered from adults (21%) and children (34%), respectively. C. parapsilosis was less common in adults (12%); C. glabrata was uncommon in children (6%). With the exception of 1 Candida lusitaniae isolate, the less common Candida species, including Candida krusei, Candida guilliermondii, Candida kefyr, Candida lipolytica, and Candida rugosa, were recovered only from adults. Specific tests to distinguish C. albicans from Candida dubliniensis were not performed for this analysis. Polyfungal isolates (i.e., 2 different Candida species yielded on (49) 655 (45) 725 (46) C. glabrata 9 (6) 304 (21) 313 (20) C. parapsilosis 49 (34) 176 (12) 225 (14) C. tropicalis 11 (8) 175 (12) 186 (12) C. krusei
73 (5) 77 (5) a More than 1 Candida species was isolated from a blood culture. (12) 176 (12) cultures of blood samples that were obtained simultaneously or sequentially) were recovered from 5% of adults and from 3% of children. Therapy. Systemic antifungal therapy was administered to 88% of the patients in the observational cohort (table 3) . For this analysis, patients were categorized into 1 of 7 treatment groups, which are listed in table 3. Among adult patients, 689 (53%) received fluconazole as initial therapy, compared with only 22 pediatric patients (15%;
). Conversely, sig-P pр .001 nificantly more children than adults received only amphotericin B therapy (61% vs. 21%;
). Only 2% of patients P pр .001 received antifungal treatment other than amphotericin B and/ or fluconazole.
Severity of illness and APACHE II scores. APACHE II scores were determined for adults from data obtained from their medical records; scores were not determined for children.
Among 1303 adult patients in the observational cohort, mean and median APACHE II scores were 18.6 and 18, respectively. In comparison, patients in the clinical trial had mean and median APACHE II scores of 16.1 and 15.0, respectively. For the observational cohort, the median value of 18 was used as a cutoff for the multivariate and univariate analyses comparing APACHE II scores with mortality rates. One-half of the adults in the observational cohort were in an ICU at the time of the initial positive blood culture result.
Survival. The survival rate among children with candidemia was significantly higher than the survival rate among adults with candidemia (76% vs. 54%;
; table 4). Sur-P ! .001 vival was analyzed according to whether patients received amphotericin B alone, fluconazole alone, amphotericin B and fluconazole (in any combination), other treatments, any antifungal therapy, or no therapy. There was no significant difference in survival rates between children who received any antifungal regimen (80%) and the overall survival rate among children (76%). Furthermore, children who received any antifungal therapy had significantly better survival rates than did adults in the same treatment group (80% vs. 59%;
). P ! .0001 Among adults, those who received fluconazole alone had significantly better survival rates than did those who received other antifungal regimens (66% vs. 55%; ); however, flu-P p .001 conazole recipients were slightly less ill, as determined by APACHE II scores (median, 18 for those who received amphotericin B and 17 for those who received fluconazole; P p ). Survival was also assessed specifically for patients infected .086 with C. glabrata for each treatment group (table 4), and there was no significant difference in survival rates between adults who received fluconazole therapy alone (66%) and those who received amphotericin B therapy alone (59% Non-parapsilosis species of Candida 25 (28) 11 (12) 463 (46) 119 (12) a Criteria included the following: (1) positive blood culture for Candida species within 48 h of death, (2) other clinical evidence of persistent candidiasis, (3) autopsy evidence of disseminated candidiasis, or (4) in the opinion of the investigator, candidiasis contributed to death. b More than 1 Candida species was isolated from a blood culture.
Overall and cause-specific mortality rates associated with each Candida species were determined (table 5). C. albicans was associated with high overall mortality among adults (47%) and children (29%) and with the highest cause-specific mortality in adults (14%). Conversely, adults with C. parapsilosis fungemia had significantly lower overall mortality rates (24% vs. 46%;
) and cause-specific mortality rates (2% vs. P ! .001 12%;
) than did those with candidemia due to other P ! .001 Candida species. Lower mortality rates among patients infected with C. parapsilosis were seen across APACHE II score groups (figure 1). Children with C. parapsilosis fungemia had a less marked difference in survival, compared with children infected with other Candida species (overall mortality, 15% Adults from whom polyfungal Candida species bloodstream isolates were recovered also had very high overall mortality rates (46%) and cause-specific mortality rates (15%). Factors associated with mortality. Risk factors associated with mortality were assessed by univariate and multivariate analyses. A large number of independent variables were significantly associated with mortality among adult patients, but, among children, only neutropenia and tracheal intubation were significant factors, according to the multivariate model. Table  6 summarizes the factors that were significantly associated with overall mortality among adults and children.
DISCUSSION
There are several important observations in this large, prospective study of candidemia. C. albicans was the most common blood isolate recovered from adults and children, but these data also confirm the emergence of non-albicans species of Candida as major causes of candidemia in tertiary care medical centers in the United States [2, 4, 9, 10, 13, 14, 24] , constituting at least one-half of the total isolates recovered from adults and children. C. glabrata constituted 120% of bloodstream isolates recovered from adults, confirming a trend recently noted in an observational study by the National Nosocomial Infection Surveillance network [14] ; however, C. glabrata was an uncommon pathogen (6%) in infants and children. Conversely, C. parapsilosis constituted more than one-third of blood isolates recovered from children but was much less common in adults.
The collective predominance of C. glabrata and C. parapsilosis in adults (33%) and children (40%), respectively, has been described by others [1-7, 11, 20, 32-36] , but these observations remain unexplained. Given the known propensity of C. parapsilosis to adhere to foreign material [37] [38] [39] , some investigators have suggested that the prevalence of C. parapsilosis in children may reflect the aggressive use of intravascular devices to treat neonates in neonatal ICUs. There is also good evidence that this organism is commonly carried on the hands of health care workers, including nurses in the neonatal ICU [10, 35, 40] and, thus, that nosocomial transmission via direct contact is likely to occur. Others have suggested that vertical transmission from infected mothers could account for the unusual prevalence of this organism in candidemic neonates. However, C. parapsilosis is rarely yielded on vaginal cultures [41, 42] , whereas C. glabrata, a common vaginal isolate, is an uncommon cause of candidemia in infants and children [10, 20, [33] [34] [35] [36] . The less common Candida species, such as C. krusei, C. lusitaniae, and C. guilliermondii, were virtually absent in the pediatric population, confirming the observations by other groups [10, 20, 33, 34, 36] .
Important risk factors for candidemia in adults and children have been well characterized [3-6, 11, 13, 15-19, 32-36, 43-47] . In this study, 95% of patients had у1 easily identifiable risk factor, and 85% had у2; however, specific risk factors were dissimilar between the 2 groups. For example, children were much more likely than adults to have been endotracheally intubated (69% vs. 48%). Several investigators have emphasized Intubation 100 (28) 43 (11.6) .038
the particular importance of endotracheal intubation as a risk factor for candidemia in pediatric patients [44] [45] [46] ; furthermore, Rowen et al. [47] recently demonstrated that endotracheal colonization in neotates with a low birth weight was associated with the development of candidemia. Earlier studies describe an overall mortality of ∼60% among adults with candidemia [3, 6, 12] , with mortality attributable to candidemia reportedly as high as 38% [12, 19] . More recent studies suggest lower overall and attributable mortality rates, which are possibly associated with the earlier recognition of candidemia and the administration of more-aggressive antifungal therapy [17, 18, 20] . In this study, overall mortality 3 months after the initial positive blood culture result was 40%, and cause-specific mortality was 12%. Despite some of the shortcomings associated with observational studies, these data may reflect a more accurate view of the current impact of candidemia on mortality, although a well-designed case-control study would be necessary to confirm this. Nonetheless, these data are important because they reflect the experience from a large group of centers during a time in which most patients received aggressive antifungal therapy.
Risk factors significantly associated with mortality, according to results of multivariate analysis, were distinct for adult and children. It is not surprising that higher APACHE II scores, neoplasia, receipt of glucocorticosteroids, and candidemia due to Candida species other than C. parapsilosis were among the most important risk factors in adults. In contrast, only neutropenia and endotracheal intubation were significantly associated with mortality among children. Selection of a specific antifungal regimen was not found to correlate with outcome in either group.
Candidemia due to C. parapsilosis was significantly less likely to be associated with mortality than was candidemia due to other Candida species, even when data were corrected for severity of illness on the basis of APACHE II scores. In contrast, candidemia due to C. albicans was associated with higher overall mortality, compared with the non-albicans species of Candida. These findings are very consistent with experimental data demonstrating that C. albicans is more virulent than either C. glabrata or C. parapsilosis in animal models [48] [49] [50] . In a recent retrospective study of patients with cancer, Viscoli et al. [21] suggested significantly higher mortality associated with C. glabrata fungemia and a trend toward poorer outcomes associated with C. tropicalis fungemia, compared with mortality and outcomes associated with fungemia due to other Candida species.
Although only approximately one-fourth of our subjects had cancer as an underlying disease, our data provide no clinical evidence to support the claim that C. glabrata or C. tropicalis bloodstream infections are associated with poorer clinical outcomes than are infections with C. albicans in a heterogeneous and seriously ill group of patients.
The choice of antifungal therapy did not appear to have a significant impact on survival among children, given the survival rate of ∼80% among those who received antifungal therapy for candidemia. Survival rates were lower among adults than among children for each therapeutic group, but adults who received fluconazole alone had a more favorable outcome than adults who received other regimens, reflecting a bias toward the administration of fluconazole therapy to patients who were less ill. Indeed, APACHE II scores were lower among patients who received initial fluconazole therapy, compared with those who received amphotericin B. We did not observe any difference in survival among patients with C. glabrata fungemia who received fluconazole versus another antifungal therapy. Thus, despite recent data that demonstrated significant azole resistance among C. glabrata clinical isolates [8, 9] , this did not translate into diminished survival rates in the current study. Amphotericin B was the drug of choice administered to the majority of children with candidemia, which reflected a traditional approach for treating a population with frequent complications associated with this disorder, including involvement of the eyes, heart, and CNS [51] . It is not surprising that patients who received no therapy had significantly higher overall mortality rates (61% and 50% among adults and children, respectively), which supports the recommendation that all candidemic patients receive antifungal therapy [31] .
Almost 1600 patients with candidemia were enrolled into the observational study and the clinical trial during the 32-month study period. However, !10% of these patients were enrolled into the clinical trial. Specific reasons for nonenrollment were not elucidated, although pediatric and neutropenic patients were categorically excluded. Mean APACHE II scores were significantly higher in the observational cohort than in the clinical trial cohort (18.6 and 16.1, respectively), suggesting either that investigators were less likely to consider these patients for receipt of randomized therapy or that more of them were ineligible for the study. Another published clinical trial on treatment of candidemia for which APACHE II scores were available demonstrated scores in a similar range [25] , suggesting that the disparity in scores between screened and enrolled patients is not unique to our clinical trial. The exclusion of sicker subjects potentially influences the interpretation of the data in these trials.
In conclusion, candidemia continues to be associated with substantial morbidity and mortality, and non-albicans species of Candida are currently the pathogens most frequently recovered from adults and children in tertiary care medical centers. Survival rates for children with candidemia are significantly better than survival rates for adults, although there are clearly other differences in survival associated with Candida species, suggesting clinically important variability in virulence. Candidemia due to C. parapsilosis is associated with significantly better survival rates, compared with survival rates associated with candidemia due to other Candida species, with the difference being most striking among adults. We did not observe any trend suggesting poorer survival rates among patients with C. glabrata fungemia, compared with fungemia due to other Candida species, nor did we demonstrate a difference in survival rates between antifungal regimens prescribed for treatment of C. glabrata fungemia. Therapy for candidemia continues to evolve, and the potential impact of the echinocandins and the expanded-spectrum triazoles could not be assessed in this study. Finally, we have demonstrated that treatment trials of candidemia in nonneutropenic adults remain feasible because of the very large number of potentially eligible patients. However, these trials must be designed to accommodate a very ill and heterogeneous population to more accurately reflect the influence of therapy on outcome. Given the significant influence of candidemia on morbidity and mortality and the difficulty in establishing a diagnosis of invasive candidiasis in many patients, clinical trials aimed at the primary prevention of invasive candidiasis in well-defined high-risk populations will become increasingly important [52] .
